Organizer
Evosep Biosystems
Evosep Biosystems
Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster. We are basing our design on years of experience with nano-UHPLC R&D and application support, critically rethinking the necessary system architectures for successful sample separation before mass spectrometric analysis.
Tags
Sample prep
LC/MS
LC/MS/MS
LC/Orbitrap
LC/HRMS
LC/QQQ
LinkedIn Logo

Targeted Workflows

RECORD | Already taken place Th, 27.4.2023
Targeted workflows are particularly interesting for identifying established biomarkers in various applications.
Go to the webinar
Evosep: Targeted Workflows
Evosep: Targeted Workflows

Targeted workflows are particularly interesting for identifying established biomarkers in various applications. The focus on these workflows, coupled with technological advancements, is continually expanding the boundaries of high-throughput targeted analysis.

Next Generation of absolute protein Quantitation in Biological Matrixes; higher multiplexicity while faster, robust and sensitive

  • Presenter: Dr. Christoph Borchers (Mcgill university)

The accurate and rapid determination of protein concentrations using multiplexed multiple reaction monitoring (MRM) with isotope-labeled internal standards has the potential to revolutionize biochemistry and medical sciences. The combination of an Evosep One LC with an Agilent QQQ6495C allows a several-fold reduction of analysis time while maintaining high multiplexicity. As an example, we show the use of a multi-protein method for the absolute quantitation of 270 proteins, combined with metabolomics and Artificial Intelligence (AI), to analyze the plasma of a COVID cohort for prediction of survival. Moreover, optimization of the Evosep/6495C combination allowed adaptation of the 270-protein MRM method to a 24-minute gradient, thus doubling the throughput compared to before.

Development of a LC-MS/MS Method for Measurement of Fusion Sarcoma Proteins in Plasma

  • Presenter: Phd. AnThony Maus (Clinical Mass Spec. Development Laboratory, Mayo Clinic)

Sarcoma is general term for a group of over 70 cancers that are classified using genomic techniques to identify characteristic gene fusions in tumor tissues. However, this technique requires relatively invasive biopsies and is not conducive to monitoring disease progression or response to treatment. Measurements of fusion protein biomarkers in plasma would overcome these limitations. We sought to develop an LC-MS/MS method capable of performing these measurements by conducting discovery experiments on cell lines with an EvoSep coupled to an Exploris 480 mass spectrometer. Using these data, we developed a targeted method and performed measurements in plasma samples.

Evosep Biosystems
LinkedIn Logo
 

Related content

Two-Step Matrix Deposition for Improved MS Imaging Resolution

Posters
| 2026 | Shimadzu (ASMS)
Instrumentation
LC/MS, LC/MS/MS, LC/TOF, LC/HRMS, MALDI, MS Imaging
Manufacturer
Shimadzu
Industries
Pharma & Biopharma

Smart Monitoring & Optimization Solutions for SMB Processes: In-Line and Off-Line Tools for SMB Systems

Technical notes
| 2026 | KNAUER
Instrumentation
HPLC
Manufacturer
KNAUER
Industries
Pharma & Biopharma

Xevo MRT P10 Mass Spectrometer

Brochures and specifications
| 2026 | Waters
Instrumentation
LC/MS, LC/MS/MS, LC/TOF, LC/HRMS
Manufacturer
Waters
Industries
Metabolomics, Proteomics , Lipidomics

Large-Volume Dilute-and-Shoot Analysis of PFAS in Drinking Water Using the Altura PFAS Column

Applications
| 2026 | Agilent Technologies
Instrumentation
Consumables, LC columns, LC/MS, LC/MS/MS, LC/QQQ
Manufacturer
Agilent Technologies
Industries
Environmental

Hey, ho, oliGO – Comparison of ion-pairing systems for oligonucleotide analysis with HPLC-UV

Applications
| 2026 | KNAUER
Instrumentation
Consumables, LC columns, HPLC
Manufacturer
KNAUER
Industries
Pharma & Biopharma
Other projects
GCMS
ICPMS
Follow us
FacebookX (Twitter)LinkedInYouTube
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike